Trial · NCT01660906
Results by group60
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 60
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| The Number of Imatinib-related Adverse Events (AEs) That Were Resolved, Improved, Remained Unchanged, or Worsened After 3 Months of Dasatinib Treatment | Dasatinib (100 mg) | Resolved | 91 | adverse event(s) | |
| The Number of Imatinib-related Adverse Events (AEs) That Were Resolved, Improved, Remained Unchanged, or Worsened After 3 Months of Dasatinib Treatment | Dasatinib (100 mg) | Improved | 2 | adverse event(s) | |
| The Number of Imatinib-related Adverse Events (AEs) That Were Resolved, Improved, Remained Unchanged, or Worsened After 3 Months of Dasatinib Treatment | Dasatinib (100 mg) | Unchanged | 27 | adverse event(s) | |
| The Number of Imatinib-related Adverse Events (AEs) That Were Resolved, Improved, Remained Unchanged, or Worsened After 3 Months of Dasatinib Treatment | Dasatinib (100 mg) | Worsened | 1 | adverse event(s) | |
| Mean Change From Baseline in Patient Reported CML Symptom Severity and Interference by MD Anderson Symptom Inventory - Chronic Myeloid Leukemia (MDASI-CML) Score After Switching to Dasatinib | Dasatinib (100 mg) | Core Symptom Severity Score, Month 3; n=37 | -1.35 | Standard Deviation 1.78 | units on a scale |
| Mean Change From Baseline in Patient Reported CML Symptom Severity and Interference by MD Anderson Symptom Inventory - Chronic Myeloid Leukemia (MDASI-CML) Score After Switching to Dasatinib | Dasatinib (100 mg) | Core Symptom Severity Score, Month 6; n=36 | -1.44 | Standard Deviation 1.84 | units on a scale |
| Mean Change From Baseline in Patient Reported CML Symptom Severity and Interference by MD Anderson Symptom Inventory - Chronic Myeloid Leukemia (MDASI-CML) Score After Switching to Dasatinib | Dasatinib (100 mg) | Core Symptom Severity Score, Month 12; n=37 | -1.06 | Standard Deviation 1.87 | units on a scale |
| Mean Change From Baseline in Patient Reported CML Symptom Severity and Interference by MD Anderson Symptom Inventory - Chronic Myeloid Leukemia (MDASI-CML) Score After Switching to Dasatinib | Dasatinib (100 mg) | Interference Score, Month 3; n=37 | -1.24 | Standard Deviation 2.36 | units on a scale |
| Mean Change From Baseline in Patient Reported CML Symptom Severity and Interference by MD Anderson Symptom Inventory - Chronic Myeloid Leukemia (MDASI-CML) Score After Switching to Dasatinib | Dasatinib (100 mg) | Interference Score, Month 6; n=35 | -1.28 | Standard Deviation 2.45 | units on a scale |
| Mean Change From Baseline in Patient Reported CML Symptom Severity and Interference by MD Anderson Symptom Inventory - Chronic Myeloid Leukemia (MDASI-CML) Score After Switching to Dasatinib | Dasatinib (100 mg) | Interference Score, Month 12; n=36 | -1.30 | Standard Deviation 2.56 | units on a scale |
| Mean Change From Baseline in Patient Reported CML Symptom Severity and Interference by MD Anderson Symptom Inventory - Chronic Myeloid Leukemia (MDASI-CML) Score After Switching to Dasatinib | Dasatinib (100 mg) | Symptom Severity Score, Month 3; n=37 | -1.73 | Standard Deviation 1.80 | units on a scale |
| Mean Change From Baseline in Patient Reported CML Symptom Severity and Interference by MD Anderson Symptom Inventory - Chronic Myeloid Leukemia (MDASI-CML) Score After Switching to Dasatinib | Dasatinib (100 mg) | Symptom Severity Score, Month 6; n=36 | -1.80 | Standard Deviation 1.85 | units on a scale |
| Mean Change From Baseline in Patient Reported CML Symptom Severity and Interference by MD Anderson Symptom Inventory - Chronic Myeloid Leukemia (MDASI-CML) Score After Switching to Dasatinib | Dasatinib (100 mg) | Symptom Severity Score, Month 12; n=37 | -1.46 | Standard Deviation 1.75 | units on a scale |
| Mean Change From Baseline in Patient Reported CML Symptom Severity and Interference by MD Anderson Symptom Inventory - Chronic Myeloid Leukemia (MDASI-CML) Score After Switching to Dasatinib | Dasatinib (100 mg) | CML-specific Symptom Severity Score, Month 3; n=37 | -2.52 | Standard Deviation 2.35 | units on a scale |
| Mean Change From Baseline in Patient Reported CML Symptom Severity and Interference by MD Anderson Symptom Inventory - Chronic Myeloid Leukemia (MDASI-CML) Score After Switching to Dasatinib | Dasatinib (100 mg) | CML-specific Symptom Severity Score, Month 6; n=36 | -2.60 | Standard Deviation 2.15 | units on a scale |
| Mean Change From Baseline in Patient Reported CML Symptom Severity and Interference by MD Anderson Symptom Inventory - Chronic Myeloid Leukemia (MDASI-CML) Score After Switching to Dasatinib | Dasatinib (100 mg) | CML-specific Symptom Severity Score,Month 12; n=36 | -2.24 | Standard Deviation 1.87 | units on a scale |
| Mean Change From Baseline in Patient Reported CML Symptom Severity and Interference by MD Anderson Symptom Inventory - Chronic Myeloid Leukemia (MDASI-CML) Score After Switching to Dasatinib | Dasatinib (100 mg) | 5 Most Severe Symptom Score, Month 3; n=37 | -1.61 | Standard Deviation 1.76 | units on a scale |
| Mean Change From Baseline in Patient Reported CML Symptom Severity and Interference by MD Anderson Symptom Inventory - Chronic Myeloid Leukemia (MDASI-CML) Score After Switching to Dasatinib | Dasatinib (100 mg) | 5 Most Severe Symptom Score, Month 6; n=36 | -1.69 | Standard Deviation 1.84 | units on a scale |
| Mean Change From Baseline in Patient Reported CML Symptom Severity and Interference by MD Anderson Symptom Inventory - Chronic Myeloid Leukemia (MDASI-CML) Score After Switching to Dasatinib | Dasatinib (100 mg) | 5 Most Severe Symptom Score, Month 12; n=37 | -1.43 | Standard Deviation 1.72 | units on a scale |
Mean Change From Baseline in Patient Reported Quality of Life Measurements by The European Organization for Research and Treatment of Cancer - Quality of Life (QoL) Questionnaire (EORTC QLQ) Score After Switching to Dasatinib | Dasatinib (100 mg) | Global Health Status/QOL, Month 6; n=36 | 0.46 | Standard Deviation 23.733 | units on a scale |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01660906/results